GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity.

IF 4.7 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Obesity Facts Pub Date : 2025-07-31 DOI:10.1159/000547055

Ozlem Celik, Dilek Yazici, Andreea Ciudin, Djuro Macut, Dragan Micic, Volkan Yumuk, Bulent Okan Yildiz

{"title":"GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity.","authors":"Ozlem Celik, Dilek Yazici, Andreea Ciudin, Djuro Macut, Dragan Micic, Volkan Yumuk, Bulent Okan Yildiz","doi":"10.1159/000547055","DOIUrl":null,"url":null,"abstract":"Background: Polycystic ovary syndrome (PCOS) is a multifaceted hormonal disorder that impacts both metabolic functions and reproductive health in women. PCOS pathophysiology is characterized by insulin resistance and chronic inflammation, which contribute to disrupted gonadotropin secretion, elevated androgen levels, and irregular ovulation. There is a bidirectional relationship between obesity and PCOS. Obesity contributes to the pathophysiology of PCOS, particularly by exacerbating insulin resistance - a core feature of the condition. Insulin resistance can lead to further weight gain and hinder successful weight loss.Summary: According to the latest international guidelines, improving insulin sensitivity and promoting weight loss are key strategies in the effective management of PCOS. GLP-1 receptor analogs (GLP-1 RAs) are a group of agents that are used in type 2 diabetes mellitus to regulate blood glucose levels, in addition to being indicated for weight loss in obesity. Thus, GLP-1 RAs may play a role in the management of PCOS, both due to weight loss effect and through pleiotropic effects like ameliorating insulin resistance, decreasing inflammation, and modulation of adiposity.Key messages: In light of these effects, this review aimed to perform a systematic search and narrative synthesis on the impact of GLP-1 receptor agonists (GLP-1 RAs) on the metabolic and reproductive outcomes in PCOS, with the goal of elucidating the mechanistic link between the action of GLP-1 RAs and the underlying pathophysiology of the condition.","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-15"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503748/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Facts","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547055","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Polycystic ovary syndrome (PCOS) is a multifaceted hormonal disorder that impacts both metabolic functions and reproductive health in women. PCOS pathophysiology is characterized by insulin resistance and chronic inflammation, which contribute to disrupted gonadotropin secretion, elevated androgen levels, and irregular ovulation. There is a bidirectional relationship between obesity and PCOS. Obesity contributes to the pathophysiology of PCOS, particularly by exacerbating insulin resistance - a core feature of the condition. Insulin resistance can lead to further weight gain and hinder successful weight loss.

Summary: According to the latest international guidelines, improving insulin sensitivity and promoting weight loss are key strategies in the effective management of PCOS. GLP-1 receptor analogs (GLP-1 RAs) are a group of agents that are used in type 2 diabetes mellitus to regulate blood glucose levels, in addition to being indicated for weight loss in obesity. Thus, GLP-1 RAs may play a role in the management of PCOS, both due to weight loss effect and through pleiotropic effects like ameliorating insulin resistance, decreasing inflammation, and modulation of adiposity.

Key messages: In light of these effects, this review aimed to perform a systematic search and narrative synthesis on the impact of GLP-1 receptor agonists (GLP-1 RAs) on the metabolic and reproductive outcomes in PCOS, with the goal of elucidating the mechanistic link between the action of GLP-1 RAs and the underlying pathophysiology of the condition.

查看原文本刊更多论文

Glp-1受体类似物对多囊卵巢综合征和肥胖患者代谢和生殖功能影响的证据

背景：多囊卵巢综合征（PCOS）是一种影响女性生殖生活和代谢的复杂内分泌疾病。多囊卵巢综合征的病理生理包括胰岛素抵抗和慢性炎症，导致促性腺激素分泌异常，雄激素过多和无排卵。多囊卵巢综合征在肥胖女性中更为常见，而肥胖在多囊卵巢综合征女性中更为常见。肥胖在多囊卵巢综合征的发展中起着重要作用，尤其是胰岛素抵抗，这是多囊卵巢综合征发展的核心，可能会导致体重增加并阻碍有效的减肥。正如最新的国际指南所提到的，改善胰岛素抵抗和减轻体重是多囊卵巢综合征治疗的重要组成部分。GLP-1受体类似物（GLP-1 RAs）是一组已开发用于2型糖尿病的药物，以降低血糖，除了用于治疗肥胖。因此，GLP-1 RAs可能在多囊卵巢综合征的治疗中发挥作用，这既是由于它们对减肥的影响，也是由于它们通过改善胰岛素抵抗、减少炎症和调节肥胖等多效性作用。考虑到这些影响，本综述旨在对GLP-1 RAs在PCOS代谢和生殖结局中的作用进行系统的搜索和叙述综合，试图提供GLP-1 RAs的作用机制与PCOS病理生理之间的机制联系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Facts 医学-内分泌学与代谢

CiteScore

6.80

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Obesity Facts'' publishes articles covering all aspects of obesity, in particular epidemiology, etiology and pathogenesis, treatment, and the prevention of adiposity. As obesity is related to many disease processes, the journal is also dedicated to all topics pertaining to comorbidity and covers psychological and sociocultural aspects as well as influences of nutrition and exercise on body weight. The editors carefully select papers to present only the most recent findings in clinical practice and research. All professionals concerned with obesity issues will find this journal a most valuable update to keep them abreast of the latest scientific developments.